MetaCap

NextCure Inc. (NXTC)

NASDAQ: NXTCHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.45-0.33 (-4.87%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NXTC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$29.53M
EPS (TTM)
-$6.78
52-week range
1.55 – 15.74
Day range
6.45 – 6.96
Volume / Avg
30.62K / 79.46K
Beta
—

52-week range

$1.55$15.74

NXTC stock today

NextCure (NXTC) closed at $6.45 on Nov 20, down 4.87% (-$0.33), versus the S&P 500's 3.70% decline. Trading was light, with 30.62K shares changing hands, about 39% of the average daily volume. Shares are 59.0% below their 52-week high of $15.74, set on Nov 24, 2025 and 316.1% above the 52-week low of $1.55, in the middle of the past year's range.

NXTC is down 54.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 38.6%. NextCure has posted a net loss over the last twelve months (EPS of -$6.78), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About NextCure

Company profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Michael S. Richman MSBA
Headquarters
Baltimore, MD
Employees
40
IPO year
2019

Financial highlights

Full financials

NextCure reported a net loss of $55.8 million, compared with a loss of $55.7 million a year earlier. Diluted earnings per share came in at -$19.65.

NextCure annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-55.84M$-55.65M$-62.72M$-74.73M$-69.39M
EPS (diluted)$-19.65$-23.88$-2.25$-2.69$-2.51

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$20.00+210.08%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-1.67 vs $-0.90
Surprise
-85.56%

NXTC news

All NXTC news

NextCure peers

Health Care sector
NXTC peer companies
CompanyPrice% ChgMarket capCompare
SERSerina Therapeutics Inc.1.12-6.67%$29.76Mvs NXTC
NNVCNanoViricides Inc.1.14-2.56%$29.13Mvs NXTC
RNTXRein Therapeutics Inc.0.3369-8.38%$29.06Mvs NXTC
ATHEAlterity Therapeutics Limited ADR1.52-8.16%$29.02Mvs NXTC
AYTUAytu BioPharma Inc.2.660.00%$28.91Mvs NXTC
PMNProMIS Neurosciences Inc.3.16-1.56%$28.43Mvs NXTC
EDSAEdesa Biotech Inc.2.00-8.05%$27.02Mvs NXTC
NSRXNasus Pharma Ltd.2.29-10.20%$26.82Mvs NXTC

Indexes, lists and sector

NextCure stock FAQ

What is NextCure's stock price today?

NXTC last traded at $6.45 as of Nov 20, 4:00 PM EST, down 4.87% on the day. Prices are delayed at least 15 minutes.

Does NextCure pay a dividend?

No. NextCure does not currently pay a regular cash dividend.

Who is NextCure's CEO?

Mr. Michael S. Richman MSBA is the chief executive officer of NextCure Inc., which has about 40 employees.

Has NXTC ever split its stock?

Yes. The most recent NXTC stock split was a 1-for-12 split on Jul 14, 2025.

What is the NXTC 52-week high?

The 52-week high for NXTC is $15.74 and the 52-week low is $1.55. The stock is currently 59.0% below its high.

Compare NXTC